Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.65 |
| ▸ | ESR1 | P03372 | 2/20 | 0.65 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.65 |
| ▸ | CA12 | O43570 | 2/20 | 0.65 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.65 |
| ▸ | CA1 | P00915 | 2/20 | 0.65 |
| ▸ | CA2 | P00918 | 2/20 | 0.65 |
| ▸ | CA3 | P07451 | 2/20 | 0.65 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.65 |
| ▸ | CA4 | P22748 | 2/20 | 0.65 |
| ▸ | CA6 | P23280 | 2/20 | 0.65 |
| ▸ | DPP4 | P27487 | 2/20 | 0.65 |
| ▸ | CA5A | P35218 | 2/20 | 0.65 |
| ▸ | CA7 | P43166 | 2/20 | 0.65 |
| ▸ | CA9 | Q16790 | 2/20 | 0.65 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.65 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | TYR | P14679 | 1/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4224730 | 1.00 | HCAR2 (0.65) | HCAR2ESR1ESR2CA12AKR1B10 | |
| SCHEMBL119184 | 1.00 | HCAR2 (0.65) | HCAR2ESR1ESR2CA12AKR1B10 | |
| Hydrochloric Acid SCHEMBL6818447 | 0.98 | HCAR2 (0.63) | HCAR2ESR1ESR2CA12AKR1B10 | |
| SCHEMBL10983583 | 0.98 | HCAR2 (0.63) | HCAR2ESR1ESR2CA12AKR1B10 | |
| SCHEMBL4805922 | 0.94 | HCAR2 (0.59) | HCAR2ESR1ESR2CA12AKR1B10 | |
| SCHEMBL11827727 | 0.94 | HCAR2 (0.59) | HCAR2ESR1ESR2CA12AKR1B10 | |
| Guanidine SCHEMBL27567957 | 0.90 | HCAR2 (0.55) | HCAR2ESR1ESR2CA12AKR1B10 | |
| Guanidine SCHEMBL27567958 | 0.90 | HCAR2 (0.55) | HCAR2ESR1ESR2CA12AKR1B10 | |
| SCHEMBL25200521 | 0.89 | CYP1B1 (0.77) | ESR1ESR2CA1CA2PKM | |
| SCHEMBL9718479 | 0.89 | MAPT (0.54) | HCAR2ESR1ESR2CA12AKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 809 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| US-12365830-B2 | Ligand-exchangeable janus nanoparticles and methods of making the same | ALLIANCE FOR SUSTAINABLE ENERGY, LLC (US) | 2025-07-22 | — | — | US | claimed |
| CN-119265945-B | Washable flame-retardant cotton fabric and preparation method thereof | 惠州市四海建城实业有限公司 | 2025-05-27 | — | — | CN | claimed |
| CN-119431432-A | Andrographolide diester derivative, preparation method and application | 西北农林科技大学 | 2025-02-14 | — | — | CN | claimed |
| CN-119265945-A | Washable flame-retardant cotton fabric and preparation method thereof | 惠州市四海建城实业有限公司 | 2025-01-07 | — | — | CN | claimed |
| CN-118955813-A | Low-temperature early-strength water reducer and preparation method thereof | 北京工业大学 | 2024-11-15 | — | — | CN | claimed |
| CN-118754842-A | Tryptophan derivative and preparation method and application thereof | 中国人民解放军北部战区总医院 | 2024-10-11 | — | — | CN | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| CN-114163313-B | Method for selectively synthesizing EZ-stilbene by coupling ruthenium-catalyzed aryl diazonium salt with cinnamic acid | 中山大学 | 2023-11-03 | — | — | CN | claimed |
| CN-116355011-A | Cinnamic acid derivative, preparation method and application thereof, and hydromagnesite composite powder, preparation method and application thereof | 江西广源新材料有限公司 | 2023-06-30 | — | — | CN | claimed |
| US-20060000778-A1 | high-performance membrane designed for the selective removal of a polar fluid (water) from less polar fluids (organic solvents), by a pervaporation using a composite membrane contaiing ultrafiltration membrane as support ( e.g. cellulose acetate) and a crosslinked copolymer of anionic, cationic monomers | MCMASTER UNIVERSITY (CA) | 2006-01-05 | — | — | US | claimed |
| US-20050256149-A1 | Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-11-17 | — | — | US | claimed |
| WO-2005102503-A1 | PERVAPORATION COMPOSITE MEMBRANES | MCMASTER UNIVERSITY (CA) | 2005-11-03 | — | — | WO | claimed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| CN-1655057-A | Photosensitive semiconductor nanocrystals, photosensitive composition comprising semiconductor nanocrystals and uses thereof | SAMSUNG ELECTRONICS CO LTD (KR) | 2005-08-17 | — | — | CN | claimed |
| US-20050161666-A1 | Photosensitive semiconductor nanocrystals, photosensitive composition comprising semiconductor nanocrystals and method for forming semiconductor nanocrystal pattern using the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2005-07-28 | — | — | US | claimed |
| US-6919325-B2 | Respiratory system disorders; synergistic mixtures | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-07-19 | — | — | US | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
| EP-1526584-A2 | Photosensitive semiconductor nanocrystals, photosensitive composition comprising semiconductor nanocrystals and method for forming semiconductor nanocrystal pattern using the same | Samsung Electronics Co., Ltd (KR) | 2005-04-27 | — | — | EP | claimed |
| US-20030130300-A1 | Respiratory system disorders; synergistic mixtures | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256149-A1 | Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts | ADRB3, ADRB1, HSD3B1 | HCAR2 1873/4885ESR1 2599/4885ESR2 2726/4885 |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | TAF9, TAF5, TAF1 | HCAR2 2828/4885ESR1 4582/4885ESR2 4815/4885 |
| US-20030130300-A1 | Respiratory system disorders; synergistic mixtures | ADRB3, ADRB1, CHRM3 | HCAR2 1526/4885ESR1 3038/4885ESR2 2772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.